Noxarin 6000 Anti-Xa IU/0.6 ml (SC Injection)

0.6 ml pre-filled syringe: ৳ 525.00

Medicine Details

Category Details
Generic Enoxaparin sodium
Company Opsonin pharma ltd
Also available as
Noxarin 2000 anti xa injection Noxarin 4000 anti xa injection Noxarin 8000 anti xa injection

Indications

  • Treatment of deep vein thrombosis, with or without pulmonary embolism
  • Treatment of unstable angina and non-Q-wave myocardial infarction
  • Prevention of thrombus formation in the extra-corporal circulation during haemodialysis
  • Prophylaxis of venous thromboembolic disease in surgical and medical patients

Composition

  • Enoxaparin Sodium BP 20 mg equivalent to 2000 anti-Xa III
  • Enoxaparin Sodium BP 40 mg equivalent to 4000 anti-Xa III
  • Enoxaparin Sodium BP 60 mg equivalent to 6000 anti-Xa IU
  • Enoxaparin Sodium BP 80 mg equivalent to 8000 anti-Xa IU

Pharmacology

Low molecular weight heparin with high anti-Xa activity and low anti-lla or antithrombin activity. Metabolised in the liver.

Dosage

  • Deep vein thrombosis:
    • Subcutaneously 100 anti-Xa IU/kg twice daily for 10 days
    • Subcutaneously 150 anti-Xa IU/kg once daily for 10 days
  • Unstable angina and non-Q-wave myocardial infarction: Subcutaneously 100 anti-Xa IU/kg twice daily for 2-8 days
  • Prevention of thrombus formation during hemodialysis: Recommended dose is 100 anti-Xa IU/kg
  • Venous thromboembolic disease in surgical patients:
    • Subcutaneously 2000 anti-Xa IU once daily for 7-10 days
    • Subcutaneously 4000 anti-Xa IU once daily for 7-10 days
    • Subcutaneously 4000 anti-Xa IU once daily for 3 weeks following initial therapy
  • Venous thromboembolic disease in medical patients: Subcutaneously 4000 anti-Xa IU once daily for 6-14 days

Administration

Instructions on self-administration including injection site preparation, selecting the dose, and injecting process

Interaction

Recommends discontinuation of agents affecting hemostasis prior to Noxarin therapy unless strictly indicated

Contraindications

Hypersensitivity to Enoxaparin Sodium, active major bleeding, and high risk of uncontrolled hemorrhage including recent hemorrhagic stroke

Side Effects

  • Haemorrhage (bleeding)
  • Thrombocytopenia
  • Skin rash at injection sites
  • Neuraxial hematomas with concurrent use of Noxarin and spinal/epidural anesthesia

Pregnancy & Lactation

Pregnancy category B. No evidence of crossing the placental barrier. Use during pregnancy only if clearly needed. Consideration for nursing mothers

Precautions & Warnings

Deep subcutaneous route administration, caution in conditions with increased potential for bleeding, platelet count measurement recommended

Use in Special Populations

  • No dose adjustment in elderly patients unless kidney function is impaired
  • Careful observation for signs and symptoms of bleeding in renal impairment patients
  • Caution in hepatically impaired patients

Overdose Effects

Hemorrhagic complications, neutralization by slow i.v. injection of protamine sulfate

Therapeutic Class

Parenteral anti-coagulants

Storage Conditions

Store in a cool and dry place, protect from light and moisture, do not store above 25°C, keep out of the reach of children

Related Brands